AAPL339.50-3.44 (-1.00%) ▼|ABBV289.08+6.40 (+2.26%) ▲|ABT102.45-1.61 (-1.55%) ▼|ACN239.12+2.19 (+0.92%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.56+0.53 (+0.29%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.34+1.93 (+0.61%) ▲|BA190.47-0.95 (-0.50%) ▼|BAC50.64+0.25 (+0.50%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.68+4.08 (+0.36%) ▲|BMY61.68+2.85 (+4.84%) ▲|BNY144.25+1.81 (+1.27%) ▲|BRK-B539.82+7.59 (+1.43%) ▲|C122.51+0.82 (+0.67%) ▲|CAT725.24-0.55 (-0.08%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.56+1.73 (+0.87%) ▲|COP145.95+0.71 (+0.49%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.43-0.02 (-0.01%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.75+2.07 (+2.23%) ▲|CVX225.71+1.34 (+0.60%) ▲|DE632.20+5.20 (+0.83%) ▲|DHR224.24-0.19 (-0.08%) ▼|DIS111.67+2.08 (+1.90%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.46-0.08 (-0.05%) ▼|FDX298.76+4.98 (+1.70%) ▲|GD344.44+3.01 (+0.88%) ▲|GE299.87-11.41 (-3.67%) ▼|GEV890.33-18.11 (-1.99%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.09-5.66 (-6.84%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.81+9.03 (+1.03%) ▲|HD315.11+5.23 (+1.69%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM241.92+5.53 (+2.34%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.36+5.57 (+2.19%) ▲|JPM335.26+1.73 (+0.52%) ▲|KO93.49+0.07 (+0.07%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,283.66+43.32 (+3.49%) ▲|LMT548.71+0.48 (+0.09%) ▲|LOW198.53+2.61 (+1.33%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.42+4.02 (+0.65%) ▲|MCD246.52+3.85 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.63+1.86 (+2.01%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.37+9.36 (+5.78%) ▲|MO74.64+0.55 (+0.74%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.40+1.93 (+1.08%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.86+0.69 (+0.88%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.88+0.67 (+1.80%) ▲|NOW149.54+4.18 (+2.88%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.14+1.55 (+1.20%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.11+0.67 (+2.28%) ▲|PG159.32+1.63 (+1.03%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.90-1.15 (-0.57%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.37+7.99 (+1.18%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|AAPL339.50-3.44 (-1.00%) ▼|ABBV289.08+6.40 (+2.26%) ▲|ABT102.45-1.61 (-1.55%) ▼|ACN239.12+2.19 (+0.92%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.56+0.53 (+0.29%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.34+1.93 (+0.61%) ▲|BA190.47-0.95 (-0.50%) ▼|BAC50.64+0.25 (+0.50%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.68+4.08 (+0.36%) ▲|BMY61.68+2.85 (+4.84%) ▲|BNY144.25+1.81 (+1.27%) ▲|BRK-B539.82+7.59 (+1.43%) ▲|C122.51+0.82 (+0.67%) ▲|CAT725.24-0.55 (-0.08%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.56+1.73 (+0.87%) ▲|COP145.95+0.71 (+0.49%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.43-0.02 (-0.01%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.75+2.07 (+2.23%) ▲|CVX225.71+1.34 (+0.60%) ▲|DE632.20+5.20 (+0.83%) ▲|DHR224.24-0.19 (-0.08%) ▼|DIS111.67+2.08 (+1.90%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.46-0.08 (-0.05%) ▼|FDX298.76+4.98 (+1.70%) ▲|GD344.44+3.01 (+0.88%) ▲|GE299.87-11.41 (-3.67%) ▼|GEV890.33-18.11 (-1.99%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.09-5.66 (-6.84%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.81+9.03 (+1.03%) ▲|HD315.11+5.23 (+1.69%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM241.92+5.53 (+2.34%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.36+5.57 (+2.19%) ▲|JPM335.26+1.73 (+0.52%) ▲|KO93.49+0.07 (+0.07%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,283.66+43.32 (+3.49%) ▲|LMT548.71+0.48 (+0.09%) ▲|LOW198.53+2.61 (+1.33%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.42+4.02 (+0.65%) ▲|MCD246.52+3.85 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.63+1.86 (+2.01%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.37+9.36 (+5.78%) ▲|MO74.64+0.55 (+0.74%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.40+1.93 (+1.08%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.86+0.69 (+0.88%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.88+0.67 (+1.80%) ▲|NOW149.54+4.18 (+2.88%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.14+1.55 (+1.20%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.11+0.67 (+2.28%) ▲|PG159.32+1.63 (+1.03%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.90-1.15 (-0.57%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.37+7.99 (+1.18%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|
10.8 C
New York
Wednesday, October 21, 2026

Tag: safety profile

newsFORsourcecompanycontentinformation1releasesmarket

Lumen Bio Reports Positive Phase 2 Results from the RePreve Clinical Trial (LMN-201 for C. difficile Infection)

- Global cure observed in 83.3% of LMN-201 recipients versus 36.4% randomized to placebo- LMN-201 treatment plus standard-of-care antibiotics demonstrated a six-fold reduction in...

Grünenthal advances proprietary Nociceptin Receptor (NOP) Agonist into Phase II trial in acute pain

Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain.Following successful Phase I results...

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy...

OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective...

Lilly’s Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative...

Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label...

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer

SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical...

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentationUpdated first-line...

New Progress — XellSmart Unveiled Phase I Results of Off-the-Shelf Parkinson’s Disease Cell Therapy at MDS & Completed Blinded Phase II Enrollment

SEOUL, South Korea and SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- New clinical data for XellSmart's off-the-shelf cell therapy for Parkinson's Disease was presented at...

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programsLatest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ®...

XtalPi Nominates Its First siRNA Preclinical Candidate for IgA Nephropathy Nine Months After Program Initiation

Preclinical data demonstrate subnanomolar silencing potency, achieving an IC50 tens of times lower than the corresponding values for two clinical-stage reference molecules targeting the...

Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs,...

The neuroendocrine prostate cancer market is expected to grow steadily, driven by the rising recognition of NEPC as an aggressive and treatment-resistant form of...

Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs,...

The neuroendocrine prostate cancer market is expected to grow steadily, driven by the rising recognition of NEPC as an aggressive and treatment-resistant form of...

Late-Breaking Clinical Trial Results Announced at VIVA 2026

LAS VEGAS, Oct. 14, 2026 /PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through...

AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn’s...

Higher rates of endoscopic remission and ulcer-free endoscopy were observed following subcutaneous SKYRIZI® (risankizumab-rzaa)treatment versus placeboiResults build on previously reported week 12 findings in...

T-MAXIMUM’s B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer

BEIJING, Oct. 12, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL ("T-MAXIMUM") today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSafety profile

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers